Chargement en cours...

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation with steroids, with increasing use of rituxim...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Goshua, George, Sinha, Pranay, Hendrickson, Jeanne E., Tormey, Christopher, Bendapudi, Pavan K., Lee, Alfred Ian
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2021
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7918179/
https://ncbi.nlm.nih.gov/pubmed/33280030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006052
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!